Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28457749 | 1.00 | KMT2A (0.44) | KMT2AALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL26062664 | 0.91 | LTA4H (0.46) | KMT2AALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31696763 | 0.91 | LTA4H (0.46) | KMT2AALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18040348 | 0.90 | FKBP1A (0.44) | KMT2AALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18040349 | 0.90 | FKBP1A (0.44) | KMT2AALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18066977 | 0.90 | FKBP1A (0.44) | KMT2AALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6592636 | 0.85 | LTA4H (0.42) | KMT2AALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL992574 | 0.84 | KCNN4 (0.43) | KMT2AALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL992573 | 0.84 | KCNN4 (0.43) | KMT2AALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2298094 | 0.84 | KCNN4 (0.43) | KMT2AALDH1A1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111526880-A | Integrin ligands and uses thereof | 箭头药业股份有限公司 | 2020-08-11 | — | — | CN | disclosed |
| EP-1057894-B1 | Esterase genes and uses of the same | SUMITOMO CHEMICAL CO (JP) | 2010-04-28 | — | — | EP | disclosed |
| EP-1316610-B1 | Preparation comprising an enzyme for asymmetrical hydrolysis of N-substituted C3-C4 cyclic imino-2-carboxylic acid ester and method of using the same | SUMITOMO CHEMICAL CO (JP) | 2006-05-03 | — | — | EP | disclosed |
| EP-1308519-B1 | Process for improving optical purity of azetidine-2-carboxylic acid | SUMITOMO CHEMICAL CO (JP) | 2006-04-19 | — | — | EP | disclosed |
| US-6936445-B2 | Enzyme preparation and method of using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-08-30 | — | — | US | disclosed |
| EP-1201653-B1 | Method for racemization of optically active azetidine-2-Carboxylate | SUMITOMO CHEMICAL CO (JP) | 2005-04-20 | — | — | EP | disclosed |
| US-6828129-B2 | Nucleotide sequences coding polypeptide for use as tool in genetic engineering | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2004-12-07 | — | — | US | disclosed |
| US-6812008-B2 | NUCLEOTIDE SEQUENCES CODING POLYPEPTIDE FOR USE IN THE GENERATION OF S-N-BENZYLAZETIDINE-2-CARBOXYLIC ACID | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-11-02 | — | — | US | disclosed |
| EP-0957089-B1 | Method for racemization of optically active azetidine-2-carboxylate | SUMITOMO CHEMICAL CO (JP) | 2003-09-17 | — | — | EP | disclosed |
| US-20030124683-A1 | Enzyme preparation and method of using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-07-03 | — | — | US | disclosed |
| US-6537790-B1 | Isolated protein of given sequence which can produce N-substituted cyclic imino acids by hydrolization | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-25 | — | — | US | disclosed |
| US-20020173013-A1 | Esterace genes and uses of the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-11-21 | — | — | US | disclosed |
| US-20020164727-A1 | Nucleotide sequences coding polypeptide for use as tool in genetic engineering | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-11-07 | — | — | US | disclosed |
| US-6410279-B1 | GENERATING PREFERENTIAL COMPOUND IN SOLUTION; OBTAIN N-SUBSTITUTED AZETIDINE-2-CARBOXYLIC ACID ESTER, INCUBATE WITH PREFERENTIAL ENZYME, RECOVER COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-06-25 | — | — | US | disclosed |
| EP-1201653-A1 | Method for racemization of optically active azetidine-2-Carboxylate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-05-02 | — | — | EP | disclosed |
| US-6166224-A | Method for racemization of optically active azetidine-2-carboxylate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-12-26 | — | — | US | disclosed |
| US-6162621-A | Process for producing optically active azetidine-2-carboxylic acid derivative | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2000-12-19 | — | — | US | disclosed |
| EP-1057894-A2 | Esterase genes and uses of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-0957089-A1 | Method for racemization of optically active azetidine-2-carboxylate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-11-17 | — | — | EP | disclosed |
| EP-0855446-A2 | Process for producing optically active azetidine-2-carboxylic acid derivative | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1998-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020164727-A1 | Nucleotide sequences coding polypeptide for use as tool in genetic engineering | IMPDH2, INHA, IMPDH1 | KMT2A 4052/4885ALDH1A1 2545/4885SLC6A2 1713/4885 |
| US-20020173013-A1 | Esterace genes and uses of the same | ACOT7, COASY, IMPA1 | KMT2A 2427/4885ALDH1A1 707/4885SLC6A2 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.